Skip to main
ATOS

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics Inc's current valuation is deemed attractive, indicating significant upside potential based on a net present value (NPV) analysis. The company's lead product candidate, oral (Z)-endoxifen, is in Phase 2 clinical development, with the potential to achieve key clinical milestones that could act as strong catalysts for stock performance. Furthermore, Atossa Therapeutics is making notable progress in its ongoing clinical trials, which enhances the outlook regarding its growth prospects and value in the oncology market.

Bears say

Atossa Therapeutics reported a net loss of $10.9 million, translating to an earnings per share (EPS) of $(1.27), which fell short of expectations compared to previous estimates. The company is facing significant financial challenges, including liquidity risks and the potential failure of its lead product candidate to prove safety and efficacy in ongoing clinical trials. Additionally, the firm confronts hurdles related to regulatory approvals, commercialization capabilities, reimbursement issues, and increasing competition, all of which contribute to a negative outlook for its stock.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.